- After controlling for confounders, stereotactic body radiation therapy (SBRT) offered similar outcomes to lobectomy in patients with stage I NSCLC.
Why this matters
- Treatment options for stage I NSCLC are often limited for elderly patients, poor surgical candidates, and those who decline surgery.
- 316 patients with stage I NSCLC received lobectomy (n=246) or SBRT (n=70).
- Median follow-up was 31.4 months for lobectomy group and 24.9 months for SBRT.
- Funding: Zhejiang Province.
- 3-year local recurrence-free survival (LRFS) rate was not significantly different between groups (97% for lobectomy vs 91.7% for SBRT; P=.768).
- Before propensity matching, the lobectomy group had a significantly better distant metastasis recurrence-free survival (DMRFS) (86.4% vs 70.8%; P=.011), overall RFS (85.4% vs 69.5%; P=.014), OS (88.2% vs 79.7%; P=.027), and cancer-specific survival (CSS) (91.3% vs 82.5%; P=.022) at 3 years compared with SBRT group.
- After propensity matching, there was no significant difference between lobectomy and SBRT in LRFS, DMRFS, RFS, OS, or CSS.
- Retrospective, single-center study.